Finch Therapeutics Group Inc Quick Ratio (FNCH) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Finch Therapeutics Group Inc   (NASDAQ: FNCH)

Finch Therapeutics Group Inc 's Quick Ratio

FNCH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 3.59 below Finch Therapeutics Group Inc average.

Within Biotechnology & Pharmaceuticals industry 89 other companies have achieved higher Quick Ratio than Finch Therapeutics Group Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 482 to 715.

Explain Quick Ratio?
How much Cash & cash equivalents FNCH´s has?
What are FNCH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FNCH Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change -53.4 % -73.5 % -81.28 % -64.67 % -36.94 %
Y / Y Cash & cash equivalent Change -52.91 % -50.19 % -64.63 % -66.26 % -67.47 %
Quick Ratio MRQ 3.59 5.93 6.15 5.9 3.56
FNCH's Total Ranking # 715 # 482 # 519 # 568 # 623
Seq. Current Liabilities Change 27.52 % -14.32 % -16.29 % -49.04 % -27.5 %
Seq. Cash & cash equivalent Change -22.77 % -17.36 % -12.7 % -15.48 % -18.31 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 90
Healthcare Sector # 367
Overall Market # 715


Quick Ratio Statistics
High Average Low
17.65 8.06 3.16
(Jun 30 2021)   (Mar 31 2023)




Financial Statements
Finch Therapeutics Group Inc 's Current Liabilities $ 4 Millions Visit FNCH's Balance sheet
Finch Therapeutics Group Inc 's Cash & cash equivalent $ 16 Millions Visit FNCH's Balance sheet
Source of FNCH's Sales Visit FNCH's Sales by Geography


Cumulative Finch Therapeutics Group Inc 's Quick Ratio

FNCH's Quick Ratio for the trailling 12 Months

FNCH Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -71.02 % -65.57 % -53.04 % -18.32 % 5.02 %
Y / Y Cash & cash equivalent TTM Growth -60.92 % -64.08 % -64.77 % -59.21 % -53.05 %
Quick Ratio TTM 5.36 4.93 4.08 3.55 3.97
Total Ranking TTM # 3638 # 3118 # 3161 # 407 # 2899
Seq. Current Liabilities TTM Growth -23.2 % -30.58 % -35.84 % -15.29 % -8.76 %
Seq. Cash & cash equivalent TTM Growth -16.57 % -16.14 % -26.15 % -24.35 % -23.33 %

Quick ratio ranking by company, industry and sector >> Back to FNCH Financial Strength Comparisons >> Go to Compare FNCH Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Finch Therapeutics Group Inc 's average Cash & cash equivalent, this led to increase in in Finch Therapeutics Group Inc 's Quick Ratio to 5.36, Quick Ratio remained below FNCH average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 160 other companies have achieved higher Quick Ratio than Finch Therapeutics Group Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 3118 to 3638.

Explain Quick Ratio?
How much Cash & cash equivalents FNCH´s has?
What are FNCH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 161
Healthcare Sector # 974
Within the Market # 3638


trailing twelve months Quick Ratio Statistics
High Average Low
14.41 6.91 4.08
(Dec 31 2021)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Iteos Therapeutics Inc   9.62 $ 571.256  Millions$ 59.394  Millions
Achilles Therapeutics Plc  9.43 $ 95.111  Millions$ 10.090  Millions
Vor Biopharma Inc   8.87 $ 85.938  Millions$ 9.688  Millions
Fate Therapeutics Inc   8.76 $ 304.879  Millions$ 34.793  Millions
Tscan Therapeutics Inc   8.52 $ 297.676  Millions$ 34.958  Millions
Caribou Biosciences Inc   8.46 $ 261.649  Millions$ 30.944  Millions
Qiagen N v   8.43 $ 1,152.992  Millions$ 136.753  Millions
Vigil Neuroscience Inc   8.06 $ 86.674  Millions$ 10.755  Millions
Krystal Biotech Inc   7.79 $ 559.612  Millions$ 71.851  Millions
Adverum Biotechnologies Inc   7.74 $ 173.827  Millions$ 22.461  Millions
Prime Medicine Inc   7.62 $ 158.175  Millions$ 20.749  Millions
Passage Bio Inc   7.41 $ 91.773  Millions$ 12.385  Millions
Tectonic Therapeutic Inc   7.12 $ 185.124  Millions$ 26.001  Millions
Scholar Rock Holding Corp  7.11 $ 190.494  Millions$ 26.789  Millions
Springworks Therapeutics Inc   7.04 $ 383.885  Millions$ 54.500  Millions
Pluri Inc   6.73 $ 29.985  Millions$ 4.454  Millions
Black Diamond Therapeutics Inc   6.67 $ 122.971  Millions$ 18.439  Millions
Atyr Pharma Inc   6.63 $ 78.482  Millions$ 11.837  Millions
Molecular Partners Ag  6.61 $ 71.244  Millions$ 10.785  Millions
Surrozen Inc   6.31 $ 37.765  Millions$ 5.983  Millions
Monte Rosa Therapeutics Inc   6.19 $ 262.205  Millions$ 42.348  Millions
Inhibrx Biosciences Inc   6.15 $ 226.860  Millions$ 36.881  Millions
X4 Pharmaceuticals Inc  6.09 $ 168.754  Millions$ 27.730  Millions
Genenta Science S p a   6.03 $ 14.179  Millions$ 2.351  Millions
Tenaya Therapeutics Inc   5.94 $ 99.303  Millions$ 16.712  Millions
Arcellx Inc   5.85 $ 516.688  Millions$ 88.290  Millions
Beam Therapeutics Inc   5.69 $ 1,008.165  Millions$ 177.333  Millions
Metagenomi Therapeutics Inc   5.68 $ 299.921  Millions$ 52.810  Millions
Fennec Pharmaceuticals Inc   5.56 $ 43.054  Millions$ 7.749  Millions
Recursion Pharmaceuticals Inc   5.51 $ 474.341  Millions$ 86.083  Millions

Date modified: 2026-09-26T07:39:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.